alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

28,980 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 9,376–9,400 of 16,067 studies scoring 30–49 out of 100 (page 376 of 643) · 28,980 in the whole library · How the 0–100 score works

Download bibliography of the first 500 of these studies, in this order: BibTeX (.bib) · RIS (.ris)

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Subjects

Authors

Names as each record prints them; the same person can appear under two spellings.

Institutions

From OpenAlex; 14,457 studies have no institution on record and are not counted here.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

Impact of Kolb’s experiential learning theory-based nursing on caregiver burden and psychological state of caregivers of dementia patients

✓ Peer-reviewed alzhub usefulness score 40 out of 100. Open Medicine 2025-01-01

Kolb’s experiential learning theory has a positive impact on alleviating the caregiving burden and reducing anxiety and depression among family caregivers of dementia patients. 1 key finding →

Participants: 55 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Sense of Coherence and Caregiver Burden Among Informal Caregivers of People with Dementia in China: The Mediating Role of Coping Strategies

✓ Peer-reviewed alzhub usefulness score 40 out of 100. Psychology Research and Behavior Management 2025-06-01

The caregiver burden was found at a moderate to severe level with the average score of 58.14(12.84). 5 key findings →

Design: cross-sectional Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Relationships Among Caregiver Burden, Psychological Flexibility Processes, and Depressive Symptoms in Family Caregivers of People with Dementia: Path Analyses

✓ Peer-reviewed alzhub usefulness score 40 out of 100. Journal of Applied Gerontology 2025-01-24

This study examined relationships among caregiver burden, depressive symptoms, and key processes related to psychological flexibility (experiential avoidance, cognitive fusion, values-driven actions, and mindfulness) in 157 family caregivers of individuals with dementia in the United States. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Designing for those who are Overlooked - Investigating long-term Impacts of Social Robotics for People with Advanced Dementia, Caregivers and Relatives in a Secured Care Environment

✓ Peer-reviewed alzhub usefulness score 40 out of 100. Proceedings of the ACM on Human-Computer Interaction 2025-01-10

This paper presents the results of a long-term exploratory study that examined the social and emotional impact of using a social robot with a variety of applications to promote activities for people with advanced dementia and their caregivers. 2 key findings →

Participants: 23 Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Competency‐based training boosts dementia knowledge and skills in home care workers

✓ Peer-reviewed alzhub usefulness score 40 out of 100. Alzheimer s & Dementia 2025-06-01

The training significantly improved caregivers' dementia knowledge and self-efficacy but did not reduce caregivers' distress and depression, nor decrease care recipients' emergency room visits and hospitalizations. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Pilot Test of Aprendiendo Juntos/Learning Together Demonstrates Improved Self-Efficacy for Providing Care Among Latino Family Caregivers of Persons Living With Dementia

✓ Peer-reviewed alzhub usefulness score 40 out of 100. Western Journal of Nursing Research 2025-08-04

Caregiver self-efficacy significantly improved in the IIG compared with the WLG ( P = .042) with a moderate effect size ( d = 0.64). 5 key findings →

Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

Cholinesterase inhibitors for patients with dementia: Patterns of prescribing and disparities in treatment

✓ Peer-reviewed alzhub usefulness score 40 out of 100. Journal of Alzheimer s Disease 2026-01-13

BackgroundCholinesterase inhibitors (ChEIs) are cornerstones of the symptomatic treatment of Alzheimer's disease (AD) and dementia with Lewy bodies (DLB) and are also prescribed for vascular dementia (VaD). 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

The Holy Grail: highlighting the need for equitable access to dementia treatments and clinical trials

✓ Peer-reviewed alzhub usefulness score 40 out of 100. The Lancet Regional Health - Western Pacific 2025-02-01

In the last 5 years significant progress has been made in potential dementia treatments, yet many of these treatments come with significant burdens on the healthcare system that may limit access to treatment and care for patients. 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

The perceptions of European geriatricians on the co-occurrence and links between dementia, delirium and frailty

✓ Peer-reviewed alzhub usefulness score 40 out of 100. European Geriatric Medicine 2025-03-15

Within the 440 included surveys, respondents particularly over-estimated frailty prevalence in older hospitalised patients, with two-thirds choosing between 41 and 80% prevalence, when the literature suggests only 23-46%, but paradoxically underestimated the frequency of frailty in people with delirium (more than three quarters of responses across 21-80%; literature suggests 71-93%). 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Disparities in Clinical Trial Participation for Hearing Loss Treatment and Cognitive Outcomes in the United States: A Scoping Review

✓ Peer-reviewed alzhub usefulness score 40 out of 100. The Laryngoscope 2025-04-26

Twenty-two studies (RCTs, non-RCTs, single arm and prospective trials) were included (n = 6-977; mean age: 72.0 years; 66.9% male). 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Racial disparities in the association of epigenetic age acceleration with the transition between normal cognition, mild cognitive impairment and dementia

✓ Peer-reviewed alzhub usefulness score 40 out of 100. Global Transitions 2025-08-07

Exposure to accelerated epigenetic aging was significantly associated with a higher risk of transition from NC to MCI as well as progression from MCI to dementia. 5 key findings →

Participants: 2,671 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Advancing dementia care: a review of Italy’s public health response within the WHO Global Action Plan and European strategies

✓ Peer-reviewed alzhub usefulness score 40 out of 100. BMJ Public Health 2025-07-01

IFAD activities led to substantial progress in dementia care services, with memory clinics, residential care facilities and daycare centres mapped, revealing regional disparities in service provision. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Digital Health Literacy and Self-Efficacy in Using Digital Health Resources Among Caregivers of Individuals with Alzheimer’s Disease and Related Dementias

✓ Peer-reviewed alzhub usefulness score 40 out of 100. Sage Open Aging 2025-12-01

This study explored digital health literacy skills, self-efficacy in utilizing digital health resources, and self-efficacy in managing personal health among caregivers of individuals with Alzheimer's disease and related dementias (ADRD). 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

The potential role of machine learning and deep learning in differential diagnosis of Alzheimer’s disease and FTD using imaging biomarkers: A review

✓ Peer-reviewed alzhub usefulness score 40 out of 100. The Neuroradiology Journal 2025-01-09

IntroductionThe prevalence of neurodegenerative diseases has significantly increased, necessitating a deeper understanding of their symptoms, diagnostic processes, and prevention strategies. 2 key findings →

Design: narrative review Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Prediction of Alzheimer's Dementia Using Soft Voting Ensemble Learning with Machine Learning

✓ Peer-reviewed alzhub usefulness score 40 out of 100. IJACI International Journal of Advanced Computing and Informatics 2025-04-16

Alzheimer's dementia (AD) is a degenerative brain disease characterized by a decline in cognitive function and memory. 1 key finding →

Design: longitudinal study Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Molecular Insights into α-Synuclein Fibrillation: A Raman Spectroscopy and Machine Learning Approach

✓ Peer-reviewed alzhub usefulness score 40 out of 100. ACS Chemical Neuroscience 2025-01-28

High Resolution Image Download MS PowerPoint Slide The aggregation of α-synuclein is crucial to the development of Lewy body diseases, including Parkinson’s disease and dementia with Lewy bodies. 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Combined with multimodal medical imaging and artificial intelligence for early diagnosis of Parkinson's disease

✓ Peer-reviewed alzhub usefulness score 40 out of 100. Frontiers in Neurology 2025-10-01

Epidemiological data show that both PD incidence rate and prevalence rate show a significant age-dependent growth trend [3]. 5 key findings →

Design: cross-sectional Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Differentiating patients with dementia from patients with depression and healthy controls using the Cognitive Functions Dementia (CFD) test set and machine learning

✓ Peer-reviewed alzhub usefulness score 40 out of 100. The Clinical Neuropsychologist 2025-06-03

Using raw data from the CFD and the GLMnet algorithm, we could accurately differentiate between DEM vs. HC with accuracies ranging up to 94.0%. 4 key findings →

Participants: 407 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 28,980 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 28,980 records, built mostly from automated pulls of Europe PMC (62.8% of the library) and OpenAlex (17.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,036 records (3.6% of the library) are not peer-reviewed — 964 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed